Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)

Abstract

IntroductionPeptide receptor radionuclide therapy (PRRT) has been proven to be effective in gastro-entero-pancreatic neuroendocrine tumours (NETs) using 90Yttrium (90Y)- or 177Lutetium (177Lu)-based somatostatin peptides, with 177Lu-DOTATATE recently licensed. There is less published evidence of PRRT in metastatic bronchial NETs. ObjectiveThe aim of this study was to evaluate the efficacy, safety and toxicity of PRRT in patients with bronchial NETs, to expand the evidence base in this rare type of tumour. Materials and methodsThis was a retrospective analysis of all patients with moderate to well-differentiated typical or atypical bronchial NETs treated at the Royal Free Hospital Nuclear Medicine Department with at least two cycles of 90Y-DOTA−OCTREOTATE and/or 177Lu-DOTA−OCTREOTATE between 2009 and 2020. Response rates, progression free survival (PFS), overall survival and toxicity were evaluated. Factors associated with treatment response were evaluated. ResultsOf the 25 patients with bronchial NETs treated with PRRT in our department between 2009–2020, 7 (28 %) had 90Y-DOTATATE and 18 (72 %) had 177Lu-DOTATATE. 44 % of patients had PRRT as third, fourth of fifth line treatment. 72 % of patients had liver metastases and 76 % skeletal metastases at baseline. Median progression-free survival (PFS) was 17 months (177Lu-DOTATATE = 18 months; 90Y-DOTATATE = 12 months) and the median overall survival was 42 months. High proliferation rate (ki-67 > 20) and low somatostatin receptor (SSR) uptake (score of 2) were associated with shorter PFS. ConclusionPRRT appears to be a safe treatment in somatostatin receptor positive bronchial NETs, even in patients who have been heavily pre-treated. The efficacy of PRRT is comparable with if not favourable to other systemic therapeutic options.